December 25, 2014 3:44 PM ET

Pharmaceuticals

Company Overview of Celtaxsys, Inc.

Company Overview

Celtaxsys, Inc., a biopharmaceutical company, engages in developing and testing drug compounds for treating cancer, and inflammatory and autoimmune diseases. Its technology manipulates immune cell migration as a treatment for cancer, inflammation, and organ/tissue rejection. The company’s drug compounds are designed to block the protective mechanisms created by certain tumors to prevent attack by immune system cells. Celtaxsys, Inc. was founded in 2007 and is based in Atlanta, Georgia.

311 Ferst Drive

Atlanta, GA 30332

United States

Founded in 2007

Phone:

404-920-0702

Fax:

404-920-0701

Key Executives for Celtaxsys, Inc.

Chief Executive Officer
Founder and Chief Financial Officer
Director of Operations
Chairman of Medical Advisory Panel and Chief Medical Officer
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Celtaxsys, Inc. Key Developments

Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer

Celtaxsys, Inc. announced the appointment of Sanjeev Ahuja, MD, MBA, FACP as Chief Medical Officer, effective November 1, 2014. Sanjeev most recently Chief Medical Officer at On Target Laboratories.

Celtaxsys, Inc. Appoints Greg Duncan as President and Chief Executive Officer

The Celtaxsys Board of Directors announced that Greg Duncan has been appointed as President and Chief Executive Officer (CEO) and will join the board of directors effective immediately. Mr. Duncan joins the company following his most recent role as an Executive Committee member and President of North America for Brussels based UCB, prior to which he served as a Senior Vice-President at Pfizer where his duties included leading US marketing, as well as President of their Latin America operations. Greg will be based in Atlanta, Georgia. Greg most recently served as an Executive Vice President at UCB, a member of UCB's Executive Committee, and President of North American Operations for UCB, Inc.

Celtaxsys, Inc. Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients

Celtaxsys, Inc. announced it is now enrolling patients for its first trial of CTX-4430 oral treatment for lung disease in Cystic Fibrosis patients. In this study, the safety and tolerability of CTX-4430 will be assessed at several dose levels when administered orally once-daily for 2 weeks. Additional assessments will include pharmacokinetics and biomarkers, as well as effects on lung function. This first CF study will be conducted at three sites in the U.K. under the oversight of Professor Stuart Elborn, MD, of Queens University, Belfast, and is slated to test four dose levels of oral once-daily CTX-4430 treatment in 36 adult CF patients.

Similar Private Companies By Industry

Company Name Region
pH Pharmaceutical, Inc. United States
Xtal BioStructures, Inc. United States
Centocor Ortho Biotech Services LLC United States
Omega Natural Science, Inc. United States
ProMedTek, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celtaxsys, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.